ANLON HEALTHCARE LIMITED (AHCL): Financials & Fundamentals History

Share Price

₹25.89

P/E

42.4x

ROCE

21.0%

Market Cap

₹1375 cr

Revenue (TTM)

₹227 cr

P/S

6.1x

P/B

6.0x

ROE

14.1%

Operating Margin

18.0%

Debt / Equity

0.2x

Promoter Holding

52.7%

12M Momentum

101.3%

52-week range

₹10.37₹37.24

58% of the way from its 52-week low to its high

Price risk

1Y volatility

54.3%

Beta vs sector

1-year daily

0.71

Balance sheet & cash

Interest cover

operating profit ÷ interest

11.2x

Share count, 1Y

+32.5%

Was the rally earned?

+101%share price, 1 yearMultiple-driven

Partly.

Most of the rise came from investors paying a higher multiple (P/E 25.2x to 42.4x); per-share earnings added 26 points.
The share count rose 46%.

Net profit growth+81 ptsNet profit rose about 75%, which lifts the price.

P/E change+75 ptsThe P/E rose from 25.2x to 42.4x, which lifts the price.

Share count change-55 ptsShare count rose 46%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with RUBICON RESEARCH

What is the price implying?

~24%annual earnings growth implied by the price

At a P/E of 42.4x, the price would imply about 24.3%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

Oct '26Fell 33% from the Sep 2026 peak to the Oct 2026 low.
Oct '26Volume reached 6.2x its 50-day median on 2026-10-08; price -5.0% that day.
Sep '26Regained the 2025-11 peak, 7 months after the low.
Sep '26Slipped to the 2nd quartile of Health Technology on operating margin (from the top quartile).
Sep '26Debt / equity halved over 12 months to 0.19x.
Sep '26Share count is up 32.5% over 12 months.
Sep '26Volume reached 62.2x its 50-day median on 2026-09-15; price +3.1% that day.
Jun '26Volume reached 13.1x its 50-day median on 2026-06-09; price +7.7% that day.

Show 3 earlier events

Mar '26Volume reached 45.6x its 50-day median on 2026-03-09; price +10.5% that day.
Feb '26Fell 36% from the Nov 2025 peak to the Feb 2026 low.
Nov '25Volume reached 11.5x its 50-day median on 2025-11-03; price +5.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

1 of 2 checks are within range, 1 near a threshold.
Tap a check to see how it is measured.

Other income reliance0%Within range

Other income as a share of pre-tax profit (trailing twelve months): 0.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate39%Near threshold

Median quarterly effective tax rate over about 2.5 years: 39.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data